Single Cell Analysis Reveals Immune Dysfunction from the Earliest Stages of CLL that can be Reversed by Ibrutinib
Demographics (2)
- AGE_ONSET - Disease onset age (phv00495861.v1.p1)
- SEX - Biological sex (phv00495857.v1.p1)
Other (11)
- ANALYTE_TYPE - Analyte Type (phv00495864.v1.p1)
- BODY_SITE - Body site where sample was collected (phv00495863.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00495856.v1.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00495866.v1.p1)
- IS_TUMOR - Tumor status (phv00495865.v1.p1)
- SAMPLE_ID - Sample ID (phv00495862.v1.p1)
- SAMPLE_ID - Sample ID (phv00495859.v1.p1)
- SUBJECT_ID - Subject ID (phv00495855.v1.p1)
- SUBJECT_ID - Subject ID (phv00495858.v1.p1)
- SUBJECT_ID - Subject ID (phv00495860.v1.p1)
- TUMOR_TREATMENT - Type of tumor treatment for sample (phv00495867.v1.p1)